|
Corrigendum
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
N. I. Cherny, R. Sullivan, U. Dafni, J. M. Kerst, A. Sobrero, C. Zielinski, E. G. E. de Vries, and M. J. Piccart
Ann Oncol published 7 September 2016, 10.1093/annonc/mdw258
Letters to the Editor
Sustained response to salvage therapy for dabrafenib-resistant metastatic Langerhans cell sarcoma
G. Lorillon, S. Mourah, L. Vercellino, C. de Margerie-Mellon, C. Pagès, L. Goldwirt, C. Lebbe, J. Tost, and A. Tazi
Ann Oncol published 8 August 2016, 10.1093/annonc/mdw299
Reply to the letter to the editor 'Erroneous conclusions about the association between light alcohol drinking and the risk of cancer: comments on Bagnardi et al.'s meta-analysis, by S.-K. Myung'
V. Bagnardi, E. Botteri, and C. La Vecchia
Ann Oncol published 12 September 2016, 10.1093/annonc/mdw295
Original articles
Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer
F. Janku, L. K. Johnson, D. D. Karp, J. T. Atkins, P. A. Singleton, and J. Moss
Ann Oncol published 29 August 2016, 10.1093/annonc/mdw317
In the retrospective analysis of two randomized trials, we demonstrated that in patients with advanced terminal cancers and opioid induced constipation, treatment with methylnaltrexone and even more so response to treatment are associated with prolonged survival compared to placebo or no response. Survival was not affected in patients with advanced terminal illness other than cancer.
Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer
T. Kinoshita, R. Muramatsu, T. Fujita, H. Nagumo, T. Sakurai, S. Noji, E. Takahata, T. Yaguchi, N. Tsukamoto, C. Kudo-Saito, Y. Hayashi, I. Kamiyama, T. Ohtsuka, H. Asamura, and Y. Kawakami
Ann Oncol published 8 August 2016, 10.1093/annonc/mdw319
A lower number of CD8+ in non-adenocarcinoma (AD), a higher FOXP3/CD4 ratio in smokers with AD, and a lower number of CD20+ in non-smokers with AD were identified as independent worse prognostic factors in patients with resected non-small-cell lung cancer (NSCLC). Evaluating the influence of histological type and cigarette smoke on the immunological environment may lead to the establishment of individualized immunotherapy for patients with NSCLC.
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
E. Vrdoljak, N. Marschner, C. Zielinski, J. Gligorov, J. Cortes, F. Puglisi, M. Aapro, L. Fallowfield, A. Fontana, M. Inbar, Z. Kahan, A. Welt, C. Lévy, E. Brain, X. Pivot, C. Putzu, A. González Martín, S. de Ducla, V. Easton, and G. von Minckwitz
Ann Oncol published 8 August 2016, 10.1093/annonc/mdw316
Final results from the randomised phase III TANIA trial in bevacizumab-pretreated metastatic breast cancer showed that although adding bevacizumab to second- and third-line chemotherapy significantly improved second-line progression-free survival (PFS) versus chemotherapy alone, third-line PFS and overall survival (secondary end points) were not significantly improved with continued bevacizumab.
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study
J. Furlanetto, W. Eiermann, F. Marmé, T. Reimer, M. Reinisch, S. Schmatloch, E. Stickeler, C. Thomssen, M. Untch, C. Denkert, G. von Minckwitz, B. Lederer, V. Nekljudova, K. Weber, S. Loibl, and V. Möbus
Ann Oncol published 8 August 2016, 10.1093/annonc/mdw315
Obese patients receiving dose-dense (dd) chemotherapy according to their real body surface area are at higher risk for severe toxicities. However, efficacy is not influenced by relative total dose intensity. Therefore, dose adjustment of dd chemotherapy is warranted in obese patients to avoid complications.
Reviews
Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues
E. Bentivegna, S. Gouy, A. Maulard, P. Pautier, A. Leary, N. Colombo, and P. Morice
Ann Oncol published 8 August 2016, 10.1093/annonc/mdw311
Conservative treatment to preserve fertility in ovarian cancer can be safely carried out for stage IA and IC grade 1 and 2 disease and stage IC1 according to the new FIGO staging system. For patients with 'less favourable' prognostic factors (grade 3, stage IC3 disease, clear-cell tumour), the safety of fertility-sparing surgery (FSS) could not be confirmed, but patients should be informed that radical treatment probably may not necessarily improve their oncological outcome because the poorest survival observed is related to the natural history of the disease and not specifically to the use of a conservative treatment. FSS should remain contraindicated for stage II/III disease (whatever the histologic subtype) but could probably be considered for stage I clear-cell tumours. The management of patients with early EOC eligible for FSS should be multidisciplinary and histological review of the ovarian tumour and surgical staging should be done by experi- enced teams.
The obese endometrial cancer patient: how do we effectively improve morbidity and mortality in this patient population?
K. Papatla, M. Huang, and B. Slomovitz
Ann Oncol published 8 August 2016, 10.1093/annonc/mdw310
Endometrial cancer patients have increased mortality from obesity-related comorbidities. Gynecologic oncologists should regularly incorporate screening and treatment methods to address this risk.
|
|
|
  |
|
|
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου